Studies on specific transient receptor potential melastatin 2 (TRPM2) channel inhibitors can deepen our understanding of the pathological mechanism of related diseases, and allow discovery of novel, effective targets and drugs for therapy. The development of TRPM2 channel inhibitors can be broadly classified into four categories with distinct characteristics: reutilization and structural modification of homologous ion channel modulators to produce a diverse array of TRPM2 channel inhibitors with strong inhibitory effects; TRPM2 channel inhibitors based on channel gating mechanism with high specificity; inhibitors identified through high-throughput screening with novel chemical structures; inhibitors developed from natural antioxidants with higher safety. In recent years, the application of computer-aided drug design has significantly accelerated the development of TRPM2 channel inhibitors. Several promising compounds such as ZA18, A1 and D9 have been discovered, and it is expected that more potent and selective TRPM2 channel inhibitor scaffolds will be discovered in the future. This article reviews the advances on the studies of TRPM2 channel inhibitors, aiming to provide insights for further research and clinical application of TRPM2 channel inhibitors.
TRPM Cation Channels/antagonists & inhibitors* ; Humans ; Drug Design

We investigated the effects of transient receptor potential M8 (TRPM8) channel on the proliferation and motility of androgen-independent prostate cancer PC-3 cells. After being permanently transfected with an empty vector and cDNA encoding the TRPM8 protein, cells were analysed for cell cycle distribution and motility using flow cytometry and scratch assay. Immunocytochemistry and Ca2+ imaging analysis revealed the overexpression of functional TRPM8 channel on both endoplasmic reticulum and plasma membrane of PC-3-TRPM8 cells. Cell cycle distribution and scratch assay analysis revealed that TRPM8 induced cell cycle arrest at the G0/G1 stage (P < 0.05) and facilitated the cell apoptosis induced by starvation (P < 0.05). Furthermore, TRPM8 inhibited the migration of PC-3-TRPM8 cells (P < 0.01) through the inactivation of focal-adhesion kinase. It appears that TRPM8 was not essential for the survival of PC-3 cells; however, the overexpression of TRPM8 had negative effects on the proliferation and migration of PC-3 cells. Thus, TRPM8 and its agonists may serve as important targets for the treatment of prostate cancer.
Adenocarcinoma ; genetics ; metabolism ; pathology ; Apoptosis ; Calcium ; metabolism ; Cell Cycle ; Cell Line, Tumor ; Cell Movement ; physiology ; Cell Proliferation ; Cell Transformation, Neoplastic ; Cytosol ; metabolism ; DNA-Binding Proteins ; genetics ; metabolism ; Epithelial Cells ; metabolism ; pathology ; Focal Adhesion Protein-Tyrosine Kinases ; antagonists & inhibitors ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Prostatic Neoplasms ; genetics ; metabolism ; pathology ; Starvation ; pathology ; TRPM Cation Channels ; genetics ; metabolism ; Transcription Factors ; genetics ; metabolism ; Transfection

Apoptosis ; Cell Cycle ; Cell Line, Tumor ; Cell Movement ; physiology ; Cell Proliferation ; Cell Transformation, Neoplastic ; DNA-Binding Proteins ; genetics ; metabolism ; Epithelial Cells ; metabolism ; pathology ; Focal Adhesion Protein-Tyrosine Kinases ; antagonists & inhibitors ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Prostatic Neoplasms ; genetics ; metabolism ; pathology ; TRPM Cation Channels ; genetics ; metabolism ; Transcription Factors ; genetics ; metabolism